icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
 
 
 
Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy
 
 
  Reported by Jules Levin
EASL 2019 April 10-14 Vienna
 
Luisa Pasulo, Martina Gambato, Angiola Spinetti, Roberta D┤Ambrosio, Massimo Puoti, Alessia Ciancio, Vito Di Marco, Vincenza Calvaruso, Colombatto Piero, Maurizia Brunetto, Monica Schiavini, Paolo Sacchi, Roberto Gulminetti, Giada Carolo, Piergiorgio Scotton, Caterina Pozzan, Maria Vinci, Mauro Vigan˛ on behalf Italian Real life HCV cirrhotic G3 Study Group (Navigatore Lombardy and Veneto, Piemonte, Tuscany, Sicily)

con

0412192

0412193

0412194